Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lion One Metals Limited stock logo
LIO
Lion One Metals
C$0.18
C$0.16
C$0.12
▼
C$0.39
C$72.51M0.3831672,449 shs43,665 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$13.49
-3.3%		$12.78
$1.39
▼
$15.88
$2.82B2.526.89 million shs4.82 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lion One Metals Limited stock logo
LIO
Lion One Metals
-2.70%-4.26%+20.00%+38.46%-51.35%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-0.07%-1.48%+26.36%+80.00%+650.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lion One Metals Limited stock logo
LIO
Lion One Metals
C$0.18
C$0.16
C$0.12
▼
C$0.39
C$72.51M0.3831672,449 shs43,665 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$13.49
-3.3%		$12.78
$1.39
▼
$15.88
$2.82B2.526.89 million shs4.82 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lion One Metals Limited stock logo
LIO
Lion One Metals
-2.70%-4.26%+20.00%+38.46%-51.35%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-0.07%-1.48%+26.36%+80.00%+650.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lion One Metals Limited stock logo
LIO
Lion One Metals
4.00
Strong BuyN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
2.33
Hold$10.00-25.87% Downside

Current Analyst Ratings Breakdown

Latest LIO, SLS, TRG, and BGFD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lion One Metals Limited stock logo
LIO
Lion One Metals
C$71.82M1.01C$0.04 per share4.14C$0.56 per share0.32
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/A$0.46 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lion One Metals Limited stock logo
LIO
Lion One Metals
-C$28.43MC$0.036.00N/AN/A14.07%4.84%-6.57%N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$26.86M-$0.21N/AN/AN/AN/A-35.91%-33.34%11/11/2026 (Estimated)

Latest LIO, SLS, TRG, and BGFD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.0450-$0.05-$0.0050-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lion One Metals Limited stock logo
LIO
Lion One Metals
N/A2.30%N/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lion One Metals Limited stock logo
LIO
Lion One Metals
17.69
1.01
11.23
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
18.83
18.83

Institutional Ownership

CompanyInstitutional Ownership
Lion One Metals Limited stock logo
LIO
Lion One Metals
0.07%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Lion One Metals Limited stock logo
LIO
Lion One Metals
8.09%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lion One Metals Limited stock logo
LIO
Lion One Metals
305402.85 millionN/ANot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
10201.95 million199.32 millionNot Optionable

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 10 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sellas-life-sciences-group-inc---sls-302875007.html
Wellington Management Group LLP Grows Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS
September 9 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-grows-stock-holdings-in-sellas-life-sciences-group-inc-sls-2026-09-09/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 8 at 5:54 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358231/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sellas-life-sciences-group-inc-sls.html
SELLAS Life Sciences Group, Inc. (SLS)
September 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SLS/latest-news/
Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-investment-in-sellas-life-sciences-group-inc-sls-2026-09-04/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sellas-life-sciences-group-inc---sls-302868614.html
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sellas-life-sciences-group-sls-010428540.html
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
September 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4639274-most-and-least-shorted-mid-to-mega-cap-healthcare-stocks-at-the-end-of-august
Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/science/biology/sellas-gears-up-to-present-preclinical-sls009-data-for-pancreatic-cancer-at-major-oncology-conference/ar-AA2bqVAL
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355136/0/en/sellas-life-sciences-to-present-preclinical-data-on-sls009-in-pancreatic-ductal-adenocarcinoma-at-the-2026-aacr-conference-on-pancreatic-cancer.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354740/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sellas-life-sciences-group-inc-sls.html
Why analysts think Sellas Life Sciences stock can gain 150% from here
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-analysts-think-sellas-life-sciences-stock-can-gain-150-from-here/ar-AA2bmp0f
Bank of America Corp DE Acquires 540,748 Shares of SELLAS Life Sciences Group, Inc. $SLS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-540748-shares-of-sellas-life-sciences-group-inc-sls-2026-09-01/
Sellas CEO Stergiou says ‘rigorous, unblinded’ data from pivotal AML trial will 'speak for itself' as REGAL catalyst nears
August 31, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/sellas-ceo-stergiou-says-rigorous-unblinded-data-from-pivotal-aml-trial-will-speak-for-itself-as-regal-catalyst-nears/ar-AA2bgXJ8
SLS stock looks like a $3 billion biotech winner—this short seller says the market has it dangerously wrong: 'Most expensive coin flip' (updated)
August 31, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/sls-stock-looks-like-a-3-billion-biotech-winner-this-short-seller-says-the-market-has-it-dangerously-wrong-most-expensive-coin-flip-updated/ar-AA2bg6cu
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's What Happened
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sellas-life-sciences-group-nasdaq-sls-shares-gap-down-heres-what-happened-2026-08-28/
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% - Still a Buy?
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sellas-life-sciences-group-nasdaq-sls-stock-price-up-88-still-a-buy-2026-08-27/
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
August 26, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/sellas-traders-see-pancreatic-cancer-race-after-rvmd-s-drug-approval-but-near-term-focus-remains-on-sls-s-leukemia-pipeline/ar-AA2b06GT
Sellas Life Sciences: A LinkedIn Post Moves the Stock While the Official Filing Stays Silent
August 26, 2026  |  ad-hoc-news.deA
SLS traders eye this important resistance zone ahead of key AML data readout
August 24, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/sls-traders-eye-this-important-resistance-zone-ahead-of-key-aml-data-readout/ar-AA2aPAYp
SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress
August 24, 2026  |  blockonomi.comhttps://blockonomi.com/sellas-life-sciences-sls-stock-rockets-255-on-phase-3-leukemia-trial-progress/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Belden logo displayed with networking cables, connectors, and server hardware in a dark data center setting.
The AI Boom Is Turning This Cable Maker Into a Stock to Watch
By Peter Frank | August 18, 2026
Berkshire Hathaway Inc. logo displayed above an office desk with icons representing various industry sectors.
Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding
By Leo Miller | August 25, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
Office lobby with the Anthropic logo mounted on a concrete wall, potted plants, and glass entrance doors.
The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
By Jeffrey Neal Johnson | August 19, 2026
Lion One Metals stock logo

Lion One Metals CVE:LIO

C$0.18 0.00 (0.00%)
As of 03:58 PM Eastern

Lion One Metals Limited engages in the acquisition, exploration, and evaluation of mineral resources in Fiji. The company's principal property is the 100% owned Tuvatu Gold project, which comprise four special prospecting licenses covering an area of approximately 13,613 hectares located on the island of Viti Levu in Fiji. Lion One Metals Limited is headquartered in North Vancouver, Canada.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$13.49 -0.46 (-3.30%)
Closing price 04:00 PM Eastern
Extended Trading
$13.50 +0.01 (+0.07%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas